UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 2, 2026
Definitive Healthcare Corp.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
Commission File Number 001-40815 |
|
|
|
Delaware |
|
86-3988281 |
(State of Incorporation) |
|
(IRS Employer Identification No.) |
|
492 Old Connecticut Path, Suite 401 |
|
|
Framingham, Massachusetts 01701 |
|
|
(Address of Principal Executive Offices) |
|
|
(508) 720-4224 |
Registrant’s telephone number, including area code |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class |
|
Trading
Symbol |
|
Name of Each Exchange on Which Registered |
Class A Common Stock, $0.001 par value |
|
DH |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On September 2, 2026, Definitive Healthcare Corp. (the “Company”) issued a press release announcing that the Special Committee (the “Special Committee”) of the Board of Directors of the Company received a non-binding proposal from Advent International, L.P., on behalf of certain of its managed funds (collectively, “Advent”), to acquire all of the outstanding shares of the Company’s Class A common stock (the “Class A Common Stock”) and all of the outstanding limited liability company interests of AIDH TopCo, LLC (the “Definitive OpCo Units”), in each case, that are not already owned by Advent and Jason Krantz, the Company’s founder and Executive Chairman for an all cash-purchase price of $1.02 per share of Class A Common Stock and an equivalent amount per Definitive OpCo Unit. A copy of the press release is attached hereto as Exhibits 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
DEFINITIVE HEALTHCARE CORP. |
|
|
|
|
September 2, 2026 |
|
By: |
/s/ Casey Heller |
Date |
|
Name: |
Casey Heller |
|
|
Title: |
Chief Financial Officer |